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Background. Data on potential variations in delivery of appropriate stroke care over time are scarce. We investigated temporal
changes in the quality of acute hospital stroke care across five national audits in Europe over a period of six years. Methods. Data
were derived fromnational stroke audits inGermany, Poland, Scotland, Sweden, andEngland/Wales/Northern Ireland participating
within the European Implementation Score (EIS) collaboration. Temporal changes in predefined quality indicators with comparable
information between the audits were investigated. Multivariable logistic regression analyses were performed to estimate adherence
to quality indicators over time. Results. Between 2004 and 2009, individual data from 542,112 patients treated in 538 centers
participating continuously over the study period were included. In most audits, the proportions of patients who were treated on a
SU, were screened for dysphagia, and received thrombolytic treatment increased over time and ranged from 2-fold to almost 4-fold
increase in patients receiving thrombolytic therapy in 2009 compared to 2004.Conclusions.A general trend towards a better quality
of stroke care defined by standardized quality indicators was observed over time. The association between introducing a specific
measure and higher adherence over time might indicate that monitoring of stroke care performance contributes to improving
quality of care.
1. Introduction
In several countries, mainly from Europe and Northern
America, stroke audits were implemented to provide infor-
mation on the quality of acute hospital care for the local
population [1–9]. Inmost of these audits, regular benchmark-
ing activities were implemented by comparing measures of
quality of care between the participating centers on a national
or regional level [10].
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Assessing potential trends in quality of stroke care over
time within existing audits might be useful for identifying
factors influencing changes in delivery of appropriate care
on the population level. For example, specific strategies
suspected to drive improvement in clinical practice and
service development [11] could be linked with variations in
quality of care observedwithin a given region.However, most
previously published audit data did not provide distinct infor-
mation of trends in quality of care over time [12–16].There are
only a few publications addressing temporal trends in quality
of care [8, 9]. In addition, variations in methodology, data
documentation, and variable definition of exiting audits in
Europe currently hamper direct comparability of data from
different national or regional audits [10].Therefore, little data
on time trends regarding delivery of appropriate stroke care
in different countries or regions is available.
We investigated variations in quality of acute stroke
care across five national audits in Europe using comparable
variable definitions and assessed time trends in delivery of
appropriate care over a period up to 6 years.
2. Methods
2.1. Data Collection. Data were derived from stroke audits
participating within the European Implementation Score
(EIS) project. The EIS Project is a European Union funded
project (number 223153) aiming at developing a European
methodology to assess the implementation of research evi-
dence into practice. The selection and the characteristics of
national or regional stroke audits participating in the EIS
project have been described previously [8]. For the present
analyses, audits providing datasets on more than two years
of documentation during the study period 2004–2009 were
included. Therefore, the Catalan Stroke Audit was excluded
from the present analysis and the following stroke audits were
included: the German Stroke Register Study Group [ADSR],
Germany, the Hospital Stroke Registry of National Program
for Prevention and Treatment of Cardiovascular Diseases
[POLKARD], Poland, the Scottish Stroke Care Audit [SSCA],
Scotland, the National Stroke Register in Sweden [Riks-
Stroke], Sweden, and the National Sentinel Audit of Stroke
[NSSA], England/Wales/Northern Ireland. An overview on
the characteristic of the participating audits was published
previously [17]. The study was limited to end at 2009 due to
the end of the EIS project.
2.2. Data Definition. The following variables were docu-
mented in a comparable way over time across at least four
of the five audits: demographics: age; sex; dependency pre-
stroke (dependent, independent); stroke subtype (ischemic
stroke [IS], intracerebral haemorrhage [ICH], and unde-
fined [UND]); admission: time interval between onset and
admission (≤3 h, ≥3 h/missing); day of admission (week-
end; weekday); comorbidities/risk factors: atrial fibrillation
[AF] (No/Yes); process of care: brain imaging (No/Yes);
intravenous treatment with tissue-plasminogen-activator [rt-
PA] (No/Yes); Stroke Unit [SU] treatment (No/Yes); testing
for swallowing disorders (NO/YES or unassessable if docu-
mented); antiplatelet therapy during hospital stay (No/Yes);
anticoagulant therapy during hospital stay or recommended
at discharge (No/Yes); length of hospital stay (days); level of
consciousness an admission or worst level during first week
(awake/disturbed). The definitions of the variables involved
in the present analysis were stable over the whole time period
in the participating audits. A standardized codebook was
developed in cooperation with audit representatives before
the data were pooled. The recoding of the variables was
subsequently verified by audit representatives. Results were
also checked by comparing outputs of this analysis with
publications (e.g., papers or reports) of the participating
audits.
2.3. Quality Indicators [QI]. Based on these variables the
following quality indicators were calculated with inclusion
and exclusion criteria proposed by a European consensus
group: screening for dysphagia (numerator: number of stroke
patients screened for swallowing disorders or patients that
are unassessable; denominator: all patients with IS, ICH, or
UND); thrombolytic therapy (numerator: number of stroke
patients treated with rt-PA; denominator: all patients with IS
aged 18–80 years); treatment on a SU (numerator: number
of stroke patients treated on a SU; denominator all patients
with IS, ICH, or UND); antiplatelet therapy (numerator:
number of patients receiving antiplatelet therapy during
hospital stay or at discharge; denominator: all patients with
IS alive at discharge and without anticoagulant treatment);
and anticoagulant therapy (numerator: number of patients
treated with anticoagulants at discharge or recommended at
discharge [Poland without recommendation at discharge];
denominator: all patients with IS and AF alive at discharge).
2.4. Statistical Analysis. For estimating the probability of
adhering to a specific quality indicator over time within a
respective audit, multivariable logistic regression analyses
were performed. Analyses were adjusted for age (age group),
sex, stroke subtype (if applicable), day of admission (weekend
versus weekday), AF, and level of consciousness on admission
(ADSR, POLKARD, Riks-Stroke) or within the first week
(NSSA). For the adjusted point estimates, corresponding 95%
confidence interval was calculated. The reference category
was the year in which information for the respective quality
indicator was available for the first time. To address a
potential selection bias by nonmandatory participation in
some of the audits, main analyses are based on centers
participating continuously over the whole study period. As
sensitivity analyses, performed calculations were repeated
with inclusion of all centers during the assessed time period.
The category “unassessable” for screening for dysphagia was
not documented in all audits.Therefore, as sensitivity analysis
for audits not documenting the category “unassessable” all
analyses were repeated restricting patients with no disturbed
level of consciousness.
For taking into account clustering of patients in cen-
ters with possibly different time trends in quality of care,
mixed effects modelling with random effects was applied.
Therefore a hierarchical logistic regression model with a
random intercept for centers was calculated with the SAS
procedure PROCGLIMMIX.The variance component of the
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Table 1: Characteristics of participating audits, 2004–2009∗.
ADSR POLKARD SSCA Riks-Stroke NSSA
Number of centers# 193 45 18 74 208
No. of patients per center per year, median (IQR)
2004 143 (75–372) 205 (160–264) 0 256 (169–435) 40 (37–40)
2005 164 (80–360) 141 (76–188) 369 (225–514) 277 (183–426) 0
2006 0 0 269 (187–501) 270 (170–418) 66 (48–79)
2007 217 (85–456) 280 (168–342)† 339 (188–514) 261 (165–423) 0
2008 253 (79–535) 51 (33–69)† 382 (210–578) 269 (165–399) 59 (50–60)
2009 346 (86–616) 0 297 (191–601) 268 (177–427) 0
∗Center participating continuously over the whole study period only; patients with missing center allocation or with missing/default year of admission
were not considered; #number of centers referring to participating center, trusts, or departments; IQR: interquartile range; †no complete calendar years of
documentation.
random intercept represents the between-centers variance.
For calculating the proportion of the total variance explained
by the level 2 variable the concept of the variance partition
coefficient (VPC) was used. The latent variables method
introduced by Snijders and Bosker [18] was used to calculate
the VPC. Statistical analyses were performed using the SAS
9.2 Software Package.
2.5. Standard Protocol Approvals, Registrations, and Patient
Consents. The study was approved by the ethics committee
of the Charite´-Universita¨tsmedizin Berlin (EA4/097/10) and
is registered by ethics committee of theMedical Faculty of the
University of Wu¨rzburg (215/11).
3. Results
Between 2004 and 2009, 930,978 patients (range between
audits: 31,723 to 660,070) from 1,170 centers (trusts, hospitals,
health boards, or departments; range between audits: 18
to 712) were registered within the participating audits. The
presented results were restricted on centers participating
continuously over the whole study period. The percentage of
centers with continuous documentation ranged from 22% to
100% between audits. Centers not participating continuously
had smaller numbers of patients (data not shown). Overall,
542,112 patients (range between audits: 31,155 to 303,023)were
documented within the 538 centers (range between audits:
18 to 208) participating continuously over the whole study
period (Table 1). The baseline characteristic of these patients
is shown in Table 2.
3.1. Variations in Quality of Care over Time. Themain results
of univariate and multivariable analyses are presented in
Table 3. A constant increase in the probability of screening
for swallowing disorders was observed within the ADSR,
Riks-Stroke, and NSSA with substantially lower absolute
numbers within the ADSR. There was no clear time trend
in the SSCA from 2005 to 2008 for screening for swallowing
disorders until an increase in 2009. Restricting analyses
to patients without disturbances of consciousness did not
change results substantially (data not shown). Rates of throm-
bolysis increased in ischemic stroke patients aged 18–80 years
in Riks-Stroke and theADSRover timewith a higher absolute
proportion of patients receiving thrombolytic therapy within
the ADSR. No clear time trend in the rate of thrombolysis
was seen for POLKARD. Probability of receiving Stroke Unit
treatment increased continuously in SSCA, Riks-Stroke, and
NSSA with highest relative increase in the NSSA. No clear
temporal patterns in antiplatelet therapy were observed in
most audits except for the ADSR where rates of antiplatelet
therapy were constantly increasing since 2007. Anticoagulant
therapy in patients with atrial fibrillation increased in the
ADSR and Riks-Stroke, both with an increase starting from
2007 onwards. No clear temporal changes in proportions
of patients receiving anticoagulation were observed for
POLKARD, the SSCA, and NSSA. No substantial differences
were observed in the participating audits regarding variations
in the investigated quality indicators over time when all
centers were included in the analyses (data not shown).
To account for between-centers variations, variance par-
tition coefficients (VPCs) are reported in Table 3. Between-
centers variations differ between the audits as well as between
quality indicators. For example, between-centers variation
is very low for antiplatelet and anticoagulant therapy but
substantially higher for treatment on a SU for some audits.
4. Discussion
For the first time, individual data from five prospective
national stroke audits in Europe were pooled and analyzed
over a 3- to 6-year time period between 2004 and 2009
when the EIS project was over. In most of the audits, a
general trend towards a better quality of stroke care defined
by standardized quality indicators was documented over the
study period, mainly for swallowing testing, thrombolytic
therapy, and Stroke Unit treatment. However, there were also
some performance measures, such as antiplatelet therapy or
anticoagulation in IS patients with AF, where no substantial
variations in quality of care over time were observed in
most of the audits. In some audits, a steeper increase from a
specific year onwards in the defined performance measures
was detected that might exceed a general constant trend
toward a better provision of quality of stroke care.
Only a few studies investigated up to now time trends in
delivery of quality of care within established audits. Similar
to our findings for Riks-Stroke and the ADSR, Ferrari et al.
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Table 2: Patient and clinical characteristics, 2004–2009, centers participating continuously over the whole study period∗.
ADSR POLKARD SSCA Riks-Stroke NSSA
(𝑛 = 303,023) (𝑛 = 31,564) (𝑛 = 34,962) (𝑛 = 141,389) (𝑛 = 31,174)
Age, median (IQR) 75 (66–82) 73 (62–80) 75 (66–83) 78 (69–84) 78 (69–85)
Female sex, % 49.4 50.9 51.3 49.3 52.5
Dependency prestroke, %
Independent 77.4 85.0 84.9 85.0 77.4
Dependent 22.5 15.0 15.1 15.0 22.6
Stroke subtype, %
Ischemic stroke 85.1 86.6 82.7 84.1 74.3
Intracerebral haemorrhage 9.0 10.5 10.6 11.8 11.7
Unknown/undefined 5.9 2.9 6.7 4.1 14.0
Interval onset-admission, %
<3 hours 29.3 19.3 # 25.2 19.7
>3 hours/missing 70.7 80.7 # 74.8 80.3
Day of admission, %
Weekday 75.7 75.8 75.1 74.9 74.1
Weekend 24.3 24.2 24.9 25.1 25.9
Atrial fibrillation, %
Yes 25.0 22.4 22.7 28.3 20.0
No 75.0 77.6 77.3 71.7 80.0
Level of consciousness, %†
Awake 83.7 72.9 # 81.5 62.9
Disturbed (drowsy to coma) 16.3 27.1 # 18.5 37.1
∗Analyses were restricted to patients with IS, ICH, or UND and without missing values in the respective variables; IQR: interquartile range; #variable
not documented or not documented in a comparable way; †level of consciousness on admission or during first day except the NSSA, here worst level of
consciousness during first week.
found a consistent increase of thrombolysis rates from 4.9%
in 2003 to 18.3% in 2011 within the Austrian stroke registry
[7]. The Registry of the Canadian Stroke Network (RCSN)
reported slightly higher thrombolysis rates compared to
our findings (14.0%, 2003–2005 [15], and 15.7%, 2003–2008)
[19]. Saposnik et al. reported a similar prescription rate of
antiplatelets at discharge (92.7%) within the RCSN compared
to our study [15]. The only difference to our analysis is that
the RCSN included oral anticoagulants in their definition for
antiplatelets. Similar anticoagulation rates were found within
the Danish Stroke Registry (2003–2011) where 41.5% had
been prescribed anticoagulants and 35.7% were registered as
having a contraindication [16]. The proportion of patients
being tested for swallowing disorders also substantially varied
in previous studies. Some studies such as the PCNASR
and the RCSN found lower screening rates for swallowing
disorders (45.5%, 2001–2004; 56.7%, 2005–2007; and 56.0%,
2003–2005, resp.) compared to our data, except theADSR [12,
15]. The PCNASR excluded patients who were on “nothing
per oral.” Higher rates of assessment of swallowing disorders
than in our study were reported from the population-based
South London Stroke Register (SLSR), where 90.4% of the
patients got a screening for swallowing disorders in 2004–
2006 and 87.9% between 2007 and 2009 [20]. The SLSR
observed also slightly higher SU admission rates between
2004 and 2006 of 76.4% and between 2007 and 2009 of 78.4%
compared to the data from the NSSA [20].
There might be a number of potential reasons causing
temporal changes of quality of acute stroke care within the
different countries such as introduction of a new health care
policy or new guidelines. For example, testing for swallowing
disorders was implemented as quality indicator within the
ADSR the first time in 2006 [21] and its documentation
within Riks-Stroke in Sweden started in 2007 [22]. A similar
increase of performance could be observed in both stroke
audits after start of the documentation, but the ADSR started
on a substantially lower level. This increase might reflect
a better performance of the individual hospitals due to
drawing attention to this measure. However, the increase
might also be caused by a better documentation of hospitals
within the audits, which might be perceived as improvement
of quality of care in itself. However, also other methods
of implementation, for example, better finance for stroke
services and restructuring of stroke services, might have been
reasons for improvement of quality of care [11]. The UK
National Stroke Strategy 2007 recommended screening for
dysphagia within 24 hours [23]. A consistent increase for
screening for dysphagia has been reported within the NSSA
already since 2006. The largest increase for thrombolysis
was documented in the Swedish audit from 2006 onwards.
Accordant to this finding, the Swedish acute care guidelines
from 2005 recommended thrombolysis as an important part
of the treatment of stroke patients [24]. The National Stroke
Strategy in the UK recommended in 2007 the timely access
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for 75% of stroke patients to an acute Stroke Unit [23]. This
figure was already nearly achieved in 2008 based on the
audit data (72.8%). Consistently high levels of antiplatelet
therapy were observed within the NSSA. The proportion of
about 97% of patients treated with antiplatelets at discharge
in the NSSA might represent a ceiling effect with the highest
possible treatment proportion. The 2004 National Clinical
Guideline for Stroke already recommended the prescription
of antiplatelet agents for all patients with ischemic stroke or
TIA who are not on anticoagulation [25]. The substantial
increase in uptake of antiplatelet therapy in ischemic stroke
patients in the ADSR between 2005 and 2007 may be
explained by the revised guideline on the topic of diagnostic
and therapy in neurology in 2005 that recommended also
antiplatelets in the early stage after stroke [26]. The between-
centers variation was mostly low, except for Stroke Unit
treatment.Differencesmight be partly explained by voluntary
participation in some of the audits (ADSR, POLKARD).
The study has limitations. Within the study, data from
existing audits across Europe were analyzed. In contrast to
other initiatives [27], there was no agreement on a common
set of variables or a commonmethod of data collection before
the study took place. In addition, data were collected using
different approaches (e.g., documentation of consecutively
admitted patients by staff members versus chart review for
defined sample of patients).Therefore, we cannot exclude that
variations in data collection methods might have introduced
some information bias in our analyses.Therewas no complete
or no comparable information over time for some of the
investigated quality indicators across all audits. In some
of the audits (e.g., ADSR or POLKARD), there were no
formal checks established for estimating completeness of case
ascertainment neither within a center nor of centers included
within a country as the participation of hospitals within
the audit initiatives was voluntary. Therefore, we cannot
exclude that some of the findings were caused by selection
biases rather than real changes in quality of care provided,
for example, by variations in case mix or patient selection
across participating centers and countries. To maintain data
accuracy, all of the audits used data validation tools such
as plausibility checks. Additionally, source data verification
was conducted by some of the audits. No outcome data
such as death or disability at 90 days could be calculated
due to the limited availability within the audits. It remains
unclear if the increasing number of patients per center
observed in some of the audits might be caused by a more
complete documentation within the center or by increasing
admission rates within the participating centers. However,
restricting analysis to centers with complete information over
the whole time period yielded similar estimates compared to
including all centers in the analyses.We had only very limited
information regarding the characteristics of the participating
centers within the audits. Therefore, we were not able to
investigate the potential influence of the center characteristics
on time trends of appropriate care delivery. Unfortunately, we
did not have comparable information on stroke severity based
on standardized instrumental scales across audits because the
audits used different scales for assessing stroke severity (e.g.,
NIHSS, Glasgow coma scale, and level of consciousness). We
therefore used level of consciousness as proxy for adjusting
for stroke severity. Furthermore, data were derived between
2004 and 2009 and the situation may have changed since
then.
5. Conclusions
Heterogeneous patterns were identified in the five participat-
ing European audits regarding trends in quality of care over
time. A general trend towards a better quality of stroke care
provided over the study period was observed in most audits.
The introduction of a specific performancemeasurewithin an
audit activity might contribute to improved quality of acute
stroke care provided over time.
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